Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  perifosine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 28 for your search:
Start Over
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Protocol 343, NCT01097018
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 218, NCT00401011
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01409, MSKCC-09058, CDR0000663573, 09-058, 8249, P30CA008748, U01CA069856, NCT01051557
Perifosine in Treating Patients With Advanced Pancreatic Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000269586, PMH-PHL-015, NCI-5983, 5983, NCT00053924
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000269901, PMH-PHL-014, NCI-5982, 5982, NCT00054145
Phase II Study of Perifosine in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1202, NCT00059982, E1202
Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000301951, NCI-03-C-0157, NCI-5970, NCT00060437
Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02798, MC0276, 5972, N01CM17104, MAYO-MC0276, NCI-5972, NCT00064324
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 217, NCT00391560
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 212, NCT00375791
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
Phase: Phase II
Type: Treatment
Status: Completed
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 214, NCT00401388
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 211, NCT00398879
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosne 228, NCT00448721
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 210, NCT00455559
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 231, NCT00498966
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Pro00015060, NCT00873457
Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I156, CAN-NCIC-IND156, CDR0000269475, NCIC-156, IND156, NCT00053781
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I155, CAN-NCIC-IND155, CDR0000269476, NCIC-155, IND155, NCT00053794
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-044, NCT00590954
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: CDR0000066960, NCI-99-C-0043, NCI-T98-0065, T98-0065, NCT00019656
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00149, MSGCC-0507, NCI-7311, MSGCC-H-27229-0507, CDR0000465368, GCC 0507, 7311, NCT00301938
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 124, NCT00398814
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Perifosine 127, NCT00415064
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2004-0970, NCT00431054
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and under
Sponsor: Other
Protocol IDs: 08-091, NCT00776867
Start Over